They are also actively investigated as therapeutic targets.205 AKT3-174aa shows decreased expression levels in GBM tissues compared to adjacent normal brain tissues and displays oncosuppressive properties: when overexpressed, it decreases GBM cell proliferation in vitro and in xenograft models. This evidence concerns the gene AKT3 and glioblastoma.